1 Carman and Ann Adams Department of Pediatrics, Wayne State University School of Medicine, Detroit, MI, USA.
2 Molecular Therapeutics Program, Karmanos Cancer Institute, Wayne State University School of Medicine, Detroit, MI, USA.
J Dent Res. 2017 Jan;96(1):17-22. doi: 10.1177/0022034516680556.
The objectives were to characterize oral cavity cancer (OCC) funding from the National Institutes of Health (NIH) with a secondary aim of comparing NIH support provided to OCC and other malignancies. NIH awards supporting OCC inquiry from 2000 to 2014 were accessed from the NIH RePORTER database. These data were used to evaluate temporal trends and the role of human papilloma virus and to determine the academic training and professional profiles of the principal investigators. Comparison of 2014 funding levels with other malignancies was also performed, controlling for incidence. Overall funding totals decreased considerably after 2009. Funding administered through the National Institute of Dental and Craniofacial Research (NIDCR) was 6.5 times greater than dollars awarded by the National Cancer Institute in 2000. During the period evaluated, NIDCR support decreased in most years, while National Cancer Institute support increased and approached NIDCR funding levels. Funding for human papilloma virus-related projects gradually rose, from 3.4% of dollars in 2000 to 2004 to 6.2% from 2010 to 2014 ( P < 0.05). A majority of principal investigators had a PhD omnia solus (57%), and 13% possessed dual PhD/clinical degrees. Among clinicians with specialty training, otolaryngologists and oral/maxillofacial pathologists garnered the most funding. OCC had a 2014 funding:incidence ratio of $785, much lower than for other malignancies. There has been increased volatility in funding support in recent years possibly due to budget cuts and sequestration. The National Cancer Institute has played an increasingly important role in supporting OCC research, concomitant with decreasing NIDCR support. Our findings suggest that OCC is underfunded relative to other non-oral cavity malignancies, indicating a need to increase the focus on rectifying the disparity.
目的是描述美国国立卫生研究院（NIH）的口腔癌（OCC）资助情况，并将 NIH 对 OCC 和其他恶性肿瘤的支持进行比较。从 NIH RePORTER 数据库中获取了 2000 年至 2014 年支持 OCC 研究的 NIH 奖项。这些数据用于评估时间趋势和人乳头瘤病毒的作用，并确定主要研究者的学术培训和专业概况。还对 2014 年的资金水平与其他恶性肿瘤进行了比较，同时控制了发病率。2009 年后，总体资助总额大幅下降。通过国家牙科和颅面研究所（NIDCR）管理的资金是 2000 年国立癌症研究所授予资金的 6.5 倍。在所评估的期间内，NIDCR 的支持在大多数年份都有所减少，而国立癌症研究所的支持则有所增加，并接近 NIDCR 的资金水平。与人类乳头瘤病毒相关项目的资金逐渐增加，从 2000 年至 2004 年的 3.4%增加到 2010 年至 2014 年的 6.2%（P<0.05）。大多数主要研究者拥有博士学位（57%），13%拥有博士/临床双学位。在具有专业培训的临床医生中，耳鼻喉科医生和口腔/颌面病理学家获得了最多的资金。OCC 的 2014 年资金：发病率比为 785，远低于其他恶性肿瘤。近年来，资金支持的波动性有所增加，可能是由于预算削减和强制削减。国立癌症研究所（National Cancer Institute）在支持 OCC 研究方面发挥了越来越重要的作用，同时 NIDCR 的支持也在减少。我们的研究结果表明，OCC 的资金相对其他非口腔恶性肿瘤不足，表明需要增加对纠正这种差距的关注。
